BriaCell Therapeutics - Warrants (24/02/2025) Accounts Payable

BriaCell Therapeutics - Warrants (24/02/2025) (BCTXW) currently reports a accounts payable of $2.2M as of April 2026. That compares with $3.3M in the prior-year period — down 33.7% year over year. Use the charts on this page to explore BriaCell Therapeutics - Warrants (24/02/2025)'s accounts payable history and peer comparisons.

BriaCell Therapeutics - Warrants (24/02/2025)'s accounts payable decreased from $3.3M to $2.2M — a 33.7% year-over-year decrease (period ending April 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BriaCell Therapeutics - Warrants (24/02/2025) reported $2.2M in accounts payable as of April 2026. That compares with $3.3M in the prior-year period — down 33.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $2.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BriaCell Therapeutics - Warrants (24/02/2025), and consider following BCTXW for alerts when major investors trade the stock.

BriaCell Therapeutics - Warrants (24/02/2025) is classified in the Healthcare sector. On accounts payable, it currently shows $2.2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BCTXW with unrelated industries.